Infinity Licenses Intellikine’s Oral PI3K Therapies for Oncology and Inflammatory Diseases
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 13 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1372 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Infinity Pharmaceuticals has in-licensed global rights to Intellikine’s portfolio of phosphoinositide 3-kinase (PI3K) inhibitors for inflammatory diseases and oncology indications in a US$488...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS